@article{04d74b6256874196a0155a6a55277a57,
title = "Evidence review and clinical guidance for the use of ziprasidone in Canada",
keywords = "Anxiety, Bipolar disorder, Depression, Dosing, Expert consensus, Off-label, Schizophrenia, Ziprasidone",
author = "Gardner, {David M.} and Murphy, {Andrea L.} and Stan Kutcher and Serge Beaulieu and Carlo Carandang and Alain Labelle and Pierre Lalonde and Ashok Malla and Heather Milliken and Claire O'Donovan and Ayal Schaffer and Jorge Soni and Taylor, {Valerie H.} and Richard Williams",
note = "Funding Information: A panel of twelve psychiatrists and two pharmacists with relevant antipsychotic related research and clinical expertise were convened on April 16, 2010 in order to discuss and synthesize suggestions for the clinical use of ziprasidone based on current research and clinical experiences. Funding was obtained as an unrestricted grant from Pfizer Canada{\textquoteright}s community investment funding opportunity [5]. DG and SK served as the co-chairs for the meeting and AM led the development of the manuscript. At no time did the manufacturer or any of its representatives have any input into the manuscript. There were no representatives present during the meeting proceedings and they were not privy to the content of any version of the manuscript. Psychiatrists involved Funding Information: This consensus project was supported by a grant from Pfizer Canada who is the manufacturer of ziprasidone. Other than providing funding for the consensus review Pfizer had no involvement in the project. No employee of Pfizer saw any content of the manuscript prior to its publications. We would like to thank Dave Carter of Multidimensional Healthcare as well as Christina Clark and Kathryn Landry for their logistical and research support throughout the project.",
year = "2013",
month = jan,
day = "24",
doi = "10.1186/1744-859X-12-1",
language = "English",
volume = "12",
journal = "Annals of General Psychiatry",
issn = "1744-859X",
publisher = "BioMed Central",
number = "1",
}
